These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 34153986)

  • 41. The heart in Fabry's disease.
    Sheppard MN
    Cardiovasc Pathol; 2011; 20(1):8-14. PubMed ID: 19919901
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?
    Perretta F; Jaurretche S
    Healthcare (Basel); 2023 Feb; 11(4):. PubMed ID: 36832983
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.
    Ferreira S; Auray-Blais C; Boutin M; Lavoie P; Nunes JP; Martins E; Garman S; Oliveira JP
    Clin Chim Acta; 2015 Jul; 447():96-104. PubMed ID: 26070511
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of fabry disease: current and emerging strategies.
    Rozenfeld P; Neumann PM
    Curr Pharm Biotechnol; 2011 Jun; 12(6):916-22. PubMed ID: 21235448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
    Lenders M; Neußer LP; Rudnicki M; Nordbeck P; Canaan-Kühl S; Nowak A; Cybulla M; Schmitz B; Lukas J; Wanner C; Brand SM; Brand E
    J Am Soc Nephrol; 2018 Dec; 29(12):2879-2889. PubMed ID: 30385651
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.
    Sakuraba H; Togawa T; Tsukimura T; Kato H
    Clin Exp Nephrol; 2018 Aug; 22(4):843-849. PubMed ID: 29288396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Late-onset and classic phenotypes of Fabry disease in males with the
    Valtola K; Hedman M; Kantola I; Walls S; Helisalmi S; Maria M; Raivo J; Auray-Blais C; Kuusisto J
    Open Heart; 2023 Mar; 10(1):. PubMed ID: 36927868
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
    Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
    G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An expert consensus document on the management of cardiovascular manifestations of Fabry disease.
    Linhart A; Germain DP; Olivotto I; Akhtar MM; Anastasakis A; Hughes D; Namdar M; Pieroni M; Hagège A; Cecchi F; Gimeno JR; Limongelli G; Elliott P
    Eur J Heart Fail; 2020 Jul; 22(7):1076-1096. PubMed ID: 32640076
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GLA Gene Mutation in Hypertrophic Cardiomyopathy with a New Variant Description: Is it Fabry's Disease?
    Chaves-Markman ÂV; Markman M; Calado EB; Pires RF; Santos-Veloso MAO; Pereira CMF; Lordsleem ABMDS; Lima SG; Markman Filho B; Oliveira DC
    Arq Bras Cardiol; 2019 Jul; 113(1):77-84. PubMed ID: 31291414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease.
    Alharbi FJ; Baig S; Rambhatla SB; Vijapurapu R; Auray-Blais C; Boutin M; Steeds R; Wheeldon N; Dawson C; Geberhiwot T
    Clin Chim Acta; 2020 Jan; 500():120-127. PubMed ID: 31654629
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fabry Nephropathy: An Evidence-Based Narrative Review.
    Del Pino M; Andrés A; Bernabéu AÁ; de Juan-Rivera J; Fernández E; de Dios García Díaz J; Hernández D; Luño J; Fernández IM; Paniagua J; Posada de la Paz M; Rodríguez-Pérez JC; Santamaría R; Torra R; Ambros JT; Vidau P; Torregrosa JV
    Kidney Blood Press Res; 2018; 43(2):406-421. PubMed ID: 29558749
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.
    Rombach SM; Aerts JM; Poorthuis BJ; Groener JE; Donker-Koopman W; Hendriks E; Mirzaian M; Kuiper S; Wijburg FA; Hollak CE; Linthorst GE
    PLoS One; 2012; 7(10):e47805. PubMed ID: 23094092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
    Rosa Neto NS; Bento JCB; Pereira RMR
    Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fabry disease: Review and experience during newborn screening.
    Hsu TR; Niu DM
    Trends Cardiovasc Med; 2018 May; 28(4):274-281. PubMed ID: 29100912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study.
    Germain DP; Nicholls K; Giugliani R; Bichet DG; Hughes DA; Barisoni LM; Colvin RB; Jennette JC; Skuban N; Castelli JP; Benjamin E; Barth JA; Viereck C
    Genet Med; 2019 Sep; 21(9):1987-1997. PubMed ID: 30723321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?
    Waldek S; Feriozzi S
    BMC Nephrol; 2014 May; 15():72. PubMed ID: 24886109
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fabry disease.
    Germain DP
    Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
    Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
    J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Chaperone molecules: The example of Fabry disease].
    Barbey F; Monney P; Dormond O
    Nephrol Ther; 2021 Apr; 17S():S11-S22. PubMed ID: 33910691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.